Global Antibody Drug Conjugates Market Report By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others) By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2020-2027

ID:VMR11210482
September 2021
Report Formats:
Global Antibody Drug Conjugates Market Overview
 
Antibody-drug conjugates (ADC) are an innovative therapeutic approach that combines monoclonal antibodies' unique, high specificity, properties, and anti-tumor activity (mAbs). Antibody-drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. These cytotoxic agents kill cancer cells and a chemical linker to attach the cytotoxic agent to the antibody. ADCs work by targeting a particular cell population without harming the other cells. The key highlights of antibody-drug conjugates include a monoclonal antibody, a stable linker, and a cytotoxic agent to target various cancers. Antibody-drug conjugates are wholly meant for cancer treatment. In recent years, cancer prevalence has grown, resulting in a parallel requirement for therapeutics. Cancer is a leading cause of death globally. In 2020, it accounted for about 10 million deaths. The most common new cancer cases were breast, lung, colon and rectum, prostate, skin, and stomach. The prevalence is projected to rise with the growing aging population and increasing consumption of tobacco and alcohol.
 
According to Value Market Research, the global antibody-drug conjugates market size was valued at about USD 3.2 billion in 2020 and is estimated to grow at a CAGR of around 26% during the forecast period 2021 to 2027.
 
Antibody-drug conjugates are gaining robust attention potential increased activity and reduced toxicity compared with traditional chemotherapies. Also, food and drug administration (FDA) approval to the companies for antibody-drug conjugates is further fuelling the market growth. To date, ten antibody-drug conjugates have received market approval, and nearly 100 investigational ADCs are presently in pre-clinical and clinical trials. In addition, the growing collaborations between research institutes and biotechnology and biopharmaceutical companies are also expected to boost market growth in upcoming years. However, the high cost of procedures, presence of other conventional treatment such as chemotherapy, radiotherapy, lack of fund is anticipated to limit the market growth.
 
The global antibody-drug conjugates market is comprised of giant players. F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Immunomedics, Inc., Progenics Pharmaceuticals Inc., and Bayer Healthcare Pharmaceuticals are vital players associated with the market.
 
Global Antibody Drug Conjugates Market Share
In this research report, the global antibody-drug conjugates market is segmented by type, application, and region.
 
Analysis, By Types
Based on types, the global antibody-drug conjugates market is monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are most promising for antibody-drug conjugates. It possesses modest antitumor efficacy as a single agent. Monoclonal antibodies have been identified to show promising effects in a vast number of cancers. The monoclonal antibodies segment is estimated to grow at a high pace during the forecast period. Growing approvals and clinical trials are anticipated to trigger segment growth. 
 
Analysis, By Application
Based on application, the global antibody-drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others. Breast cancer was the leading segment in 2020 and is likely to witness considerable growth over the forecast period. Antibody-drug conjugates are widely adopted for breast cancer treatment due to their effectiveness. Growing research efforts to identify novel targets and combination with other treatment modalities will further raise demand.
 
Analysis, By Region
Based on region, the global antibody-drug conjugates market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the global antibody-drug conjugates market. North America has a strong pharmaceutical & healthcare infrastructure and is home to many prominent players and end-users. The rising prevalence of disease, easy access to treatment, and growing investment in cancer therapy research drive regional growth. As per National Cancer Institute Statistics, in 2020, an estimated 1,806,590 new cancer cases were diagnosed in the US, and 606,520 people died from the disease. Regional players are adopting collaboration strategies to gain access to more detailed research and a high success rate.
 
Market Segmentation covered in the Report:
By Types
  • Monoclonal Antibodies
  • Linker
  • Drug/Toxin
  • Others
 
By Application
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumour
  • Others
 
 
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
 
METHODOLOGY

This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. 

If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . ANTIBODY DRUG CONJUGATES – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 By Types
           3.7.2 By Application
           3.7.3 By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL ANTIBODY DRUG CONJUGATES MARKET ANALYSIS BY TYPES
       6.1 Overview by Types
       6.2 Historical and Forecast Data
       6.3 Analysis by Types
       6.4 Monoclonal Antibodies Market by Regions
       6.6 Linker Market by Regions
       6.5 Drug/Toxin Market by Regions
       6.7 Others Market by Regions
 
7 . GLOBAL ANTIBODY DRUG CONJUGATES MARKET ANALYSIS BY APPLICATION
       7.1 Overview by Application
       7.2 Historical and Forecast Data
       7.3 Analysis by Application
       7.4 Blood Cancer Market by Regions
       7.5 Breast Cancer Market by Regions
       7.6 Ovarian Cancer Market by Regions
       7.7 Lung Cancer Market by Regions
       7.8 Brain Tumour Market by Regions
       7.9 Others Market by Regions
 
8 . GLOBAL ANTIBODY DRUG CONJUGATES MARKET ANALYSIS BY GEOGRAPHY
       8.1. Regional Outlook
       8.2. Introduction
       8.3. North America
           8.3.1. Overview, Historic and Forecast Data
           8.3.2. North America By Segment
           8.3.3. North America By Country
           8.3.4. United State
           8.3.5. Canada
           8.3.6. Mexico
       8.4. Europe
           8.4.1. Overview, Historic and Forecast Data
           8.4.2. Europe by Segment
           8.4.3. Europe by Country
           8.4.4. United Kingdom
           8.4.5. France
           8.4.6. Germany
           8.4.7. Italy
           8.4.8. Russia
           8.4.9. Rest Of Europe
       8.5. Asia Pacific
           8.5.1. Overview, Historic and Forecast Data
           8.5.2. Asia Pacific by Segment
           8.5.3. Asia Pacific by Country
           8.5.4. China
           8.5.5. India
           8.5.6. Japan
           8.5.7. South Korea
           8.5.8. Australia
           8.5.9. Rest Of Asia Pacific
       8.6. Latin America
           8.6.1. Overview, Historic and Forecast Data
           8.6.2. Latin America by Segment
           8.6.3. Latin America by Country
           8.6.4. Brazil
           8.6.5. Argentina
           8.6.6. Peru
           8.6.7. Chile
           8.6.8. Rest of Latin America
       8.7. Middle East & Africa
           8.7.1. Overview, Historic and Forecast Data
           8.7.2. Middle East & Africa by Segment
           8.7.3. Middle East & Africa by Country
           8.7.4. Saudi Arabia
           8.7.5. UAE
           8.7.6. Israel
           8.7.7. South Africa
           8.7.8. Rest Of Middle East And Africa
 
9 . COMPETITIVE LANDSCAPE OF THE ANTIBODY DRUG CONJUGATES COMPANIES
       9.1. Antibody Drug Conjugates Market Competition
       9.2. Partnership/Collaboration/Agreement
       9.3. Merger And Acquisitions
       9.4. New Product Launch
       9.5. Other Developments
 
10 . COMPANY PROFILES OF ANTIBODY DRUG CONJUGATES INDUSTRY
       10.1. Company Share Analysis
       10.2. Market Concentration Rate
       10.3. F. Hoffman-La Roche Ltd.
           10.3.1. Company Overview
           10.3.2. Financials
           10.3.3. Products
           10.3.4. Recent Developments
       10.4. Novartis AG
           10.4.1. Company Overview
           10.4.2. Financials
           10.4.3. Products
           10.4.4. Recent Developments
       10.5. Takeda Pharmaceutical Company Limited
           10.5.1. Company Overview
           10.5.2. Financials
           10.5.3. Products
           10.5.4. Recent Developments
       10.6. Pfizer Inc.
           10.6.1. Company Overview
           10.6.2. Financials
           10.6.3. Products
           10.6.4. Recent Developments
       10.7. Seattle Genetics Inc.
           10.7.1. Company Overview
           10.7.2. Financials
           10.7.3. Products
           10.7.4. Recent Developments
       10.8. Genentech Inc.
           10.8.1. Company Overview
           10.8.2. Financials
           10.8.3. Products
           10.8.4. Recent Developments
       10.9. Immunogen Inc.
           10.9.1. Company Overview
           10.9.2. Financials
           10.9.3. Products
           10.9.4. Recent Developments
       10.10. Immunomedics Inc.
           10.10.1. Company Overview
           10.10.2. Financials
           10.10.3. Products
           10.10.4. Recent Developments
       10.11. Progenics Pharmaceuticals Inc.
           10.11.1. Company Overview
           10.11.2. Financials
           10.11.3. Products
           10.11.4. Recent Developments
       10.12. Bayer Healthcare Pharmaceuticals
           10.12.1. Company Overview
           10.12.2. Financials
           10.12.3. Products
           10.12.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
 LIST OF TABLES
 

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  • COVID-19: Micro and Macro Factor Analysis
  • Analysis by Types (USD MN)
  • Monoclonal Antibodies Market by Geography (USD MN)
  • Linker Market by Geography (USD MN)
  • Drug/Toxin Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Analysis Market by Application (USD MN)
  • Blood Cancer Market by Geography (USD MN)
  • Breast Cancer Market by Geography (USD MN)
  • Ovarian Cancer Market by Geography (USD MN)
  • Lung Cancer Market by Geography (USD MN)
  • Brain Tumour Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Global Antibody Drug Conjugates Market by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton
 
 
 LIST OF FIGURES
 
  • Research Scope of Antibody Drug Conjugates Report
  • Market Research Process
  • Market Research Methodology
  • Global Antibody Drug Conjugates Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Types
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Types (USD MN)
  • Monoclonal Antibodies Market by Geography (USD MN)
  • Linker Market by Geography (USD MN)
  • Drug/Toxin Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Blood Cancer Market by Geography (USD MN)
  • Breast Cancer Market by Geography (USD MN)
  • Ovarian Cancer Market by Geography (USD MN)
  • Lung Cancer Market by Geography (USD MN)
  • Brain Tumour Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Company Market Share Analysis, 2020
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials